NCT05985174 is a NA clinical trial of CD64 , HLA-DR in Neonatal Sepsis, sponsored by Sohag University.

Who is sponsoring NCT05985174?

NCT05985174 is sponsored by Sohag University.

What drugs are being tested in NCT05985174?

Interventions in NCT05985174: CD64 , HLA-DR.

What condition does NCT05985174 study?

NCT05985174 studies Neonatal Sepsis.

Is NCT05985174 still recruiting?

NCT05985174 is currently status unknown. Last updated 14 August 2023.

Last reviewed 2023-08-14 · How we verify

NCT05985174

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Role of Neutrophil CD64 and Monocyte HLA-DR Markers in the Dignosis of Neonatal Sepsis

Status unknown NA Last updated 14 August 2023

What this trial tests

NA trial testing CD64 , HLA-DR in Neonatal Sepsis in 50 participants. Status unknown.

Timeline

1 August 2023

Primary endpoint
1 August 2024

1 August 2024

Quick facts

Lead sponsor	Sohag University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	50
Start date	1 August 2023
Primary completion	1 August 2024
Estimated completion	1 August 2024
Sites	1 location across Egypt

Drugs / interventions tested

CD64 , HLA-DR

Conditions studied

Neonatal Sepsis — all drugs for Neonatal Sepsis →

Sponsor

Sohag University

Who can join

Adults 1 Day to 28 Days, any sex, with Neonatal Sepsis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neonatal septicemia remains one of the main causes of neonatal morbidity and mortality . Sepsis which is caused by a dysregulated host response to an infectious trigger leading to a life threatening organ dysfunction was declared by the World Health Organization (WHO) on May 2017 as a global health priority that requires resolution for its prevention , dignosis , and management (Monneret et al., 2019). Despite the advances in perinatal and neonatal sepsis remains high and the outcome is still sever (Chirio et al.,2011) . HLA-DR is on the surface of monocyte \\ macrophages , dendritic cells, and B cells and plays a crucial role in adaptive immune response , More than 30 years ago , researches proved an association between the low level of HLA-DR and the development of sepsis (Cheadle at al .,1991) . A decreased expression of mHLA-DR molecules has been associated with immunoparalysis , which is an inflammatory immune responce that occurs in sepsis .(Pradhan et al.,2016).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Neonatal Sepsis

Currently open trials in the same condition.

NCT07421323 — Chlorhexidine Gluconate and Alcohol Hand Rubbing on Healthcare-associated Infection · NA · recruiting
NCT06592586 — A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women · Phase 2, PHASE3 · active not recruiting

Other Sohag University trials

Trials by the same sponsor.

NCT07119905 — Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patie · not yet recruiting
NCT07512219 — Comparison Between Greater Occipital Nerve Block and Pulsed Radiofrequency in the Management of Chronic Migraine · NA · not yet recruiting
NCT07519694 — Comparative Study Between Different Additives to Lidocaine 2٪ for Peribulbar Block in Vitreoretinal Surgery · NA · not yet recruiting
NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
NCT07523386 — Compartive Study Between Cannulated Screw and Kws in Fixation of Distal Radius · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05985174 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sohag University
Last refreshed: 14 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05985174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing